101 STRIDE: phase III study of therapeutic cancer vaccine L-BLP25 with hormonal treatment as first-line therapy for women with hormone receptor-positive, inoperable, locally advanced, recurrent, or metastatic breast cancer

2010 ◽  
Vol 8 (3) ◽  
pp. 87-88
Author(s):  
W. Eiermann ◽  
D. Miles ◽  
T. Gilewski ◽  
M. Trudeau ◽  
B. Xu ◽  
...  
Keyword(s):  
Locally Advanced ◽  
Metastatic Breast ◽  
Hormonal Treatment ◽  
Phase Iii ◽  
First Line ◽  
Therapeutic Cancer Vaccine ◽  
First Line Therapy ◽  
Hormone Receptor Positive ◽  
Line Therapy ◽  
Phase Iii Study

Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+ metastatic breast cancer (MBC): A quality-of-life (QOL) analysis

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1039-1039 ◽  
Author(s):  
B. N. Sherif ◽  
B. Sherrill ◽  
M. Amonkar ◽  
Y. Wu ◽  
J. Maltzman ◽  
...  
Keyword(s):  
Hormone Receptor ◽  
Patient Population ◽  
Metastatic Breast ◽  
Analysis Of Covariance ◽  
Phase Iii ◽  
First Line ◽  
First Line Therapy ◽  
Hormone Receptor Positive ◽  
Line Therapy ◽  
The Impact

1039 Background: A phase III randomized double-blind multicenter trial compared lapatinib plus letrozole (L+Let) with letrozole plus placebo (Let), as first-line therapy for hormone receptor positive (HR+) MBC. Median PFS, the primary endpoint of the study, in patients who were HER2+ was significantly prolonged for L+Let compared with Let (8.2 vs 3 months, Hazard Ratio (95% CI)=0.71(0.53,0.96), p=0.019). This analysis focuses on the impact of treatments on QOL in the HER2+ subgroup. Methods: QOL outcomes included the Functional Assessment of Cancer Therapy-Breast (FACT-B) total, FACT-general (FACT-G), and trial outcome index (TOI) scores assessed at screening, every 12 weeks and at withdrawal. Higher scores indicate better QOL. Changes from baseline were analyzed using analysis of covariance. In a responder analysis, patients achieving minimally important differences in QOL scores (QOL responders) were compared with Fisher's exact test. Results: Among 1,286 patients, 219 were identified as HER2+ (L+Let n=111; Let n=108). Baseline QOL scores were comparable in the two arms. In this population, mean changes in subscale and total QOL scores were generally stable over time in both treatment arms for patients who stayed on study. For example, on the FACT-B, the average change from baseline in both groups was positive at all scheduled visits through Week 48 and the maximum difference between arms was 2.6 points (CI: -5.8, 11). There were no significant differences between the two treatment arms in percentage of QOL responders (Table). Conclusions: The addition of lapatinib to letrozole significantly increases PFS while maintaining QOL when compared with letrozole alone thus confirming the clinical benefit of the combination therapy in the HR+, HER2+ MBC patient population. This combination provides an effective option in this patient population by maintaining QOL and delaying the need for chemotherapy and its accompanying side effects. [Table: see text] [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document